Oxford BioDynamics reports data for predicting inadequate responders to methotrexate

Oxford BioDynamics plc (LSE:OBD) and colleagues reported that the presence of a five-marker Chromosome Confirmation Signature (CCS) in the blood of patients with early rheumatoid arthritis as detected by the company's EpiSwitch epigenetic biomarker platform was able to predict inadequate responses to methotrexate. In a validation cohort of 19 patients with early RA, the five-marker CSS showed a positive predictive value (PPV) of 90%, a negative predictive value (NPV) of 66.7%, sensitivity of 75% and specificity of 85.7% for detecting non-responders to methotrexate. Data were published in the Journal of Translational Medicine...